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1. Introduction 
Somatomedins, a class of 5000-10 000 molecular 
mass peptide hormones which function as growth 
factors in mediating the effects of pituitary growth 
hormone [l-3], circulate in human and rat serum 
complexed to specific high kf, binding proteins 
[4-71. 
There appear to be at least two species of SmBPs*, 
a larger (fW, x 150 000) which is growth hormone 
dependent and a smaller (M, = 60 000) which is not. 
Acid treatment converts the higher MI species to the 
lower one and dissociates Sm from both [5-71. 
Both Sm and SmBp are synthesized by the liver 
in vivo [8] and by primary hepatocyte cultures [9] 
and a line of transformed Buffalo rat liver cell, BRG3A 
in vitro. The latter cells produce the Sm, multiplica- 
tion-stimulating activity [IO], and a single SmBP 
comparable to the smaller Mr species found in serum 
[6,11]. A clone of these cells, BRL-3A-2, produces 
the SmBP but, in contrast, no MSA [6]. 
The present study is the first to report the isola- 
tion and partial characterization of a SmBP (M, z 
45 000) synthesized by a line of rat hepatoma cells, 
H-35 Rueber, which,like the BRL3A-2 cells, produce 
no detectable Sm 1151. 
2. Materials and methods 
2.1. Cell culture 
Rat Rueber H-35 hepatoma cells were grown as 
*Abbreviations: Sm, somatomedin; SmBP, somatomedin- 
binding protein; ‘aSI-IGF-I, ‘*SI-labeled insuiin-like growth 
factor I; SFM, serum-free medium; MSA, multiplication- 
stimulating activity ;Mr, relative molecular mass 
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monolayers in Richter’s Imemzo medium containing 
insulin (4 pg/ml) (Associated Biomedic Systems, Inc., 
Buffalo) supplemented with NaHCOa (2.2 g/l), plus 
10% tryptose phosphate broth (Difco) and 5% fetal 
calf serum (Gibco). At the time of cell confluence 
(5-6 days), the plating medium was replaced with 
25 ml of serum-free medium which, after a period of 
18 h, was discarded. Fresh SFM was added and har- 
vested successively at 48-h intervals, and aliquots of 
this ‘conditioned’ medium frozen and lyoph~ized. 
2.2. Somatomedins 
Highly purified (approx. 200 pU/c(g) Sm, insulin- 
like growth factor I (gift of Dr RenC Humble), was 
iodinated (spec. act. x 50 ~Ci/~~ by the chloramine 
T method [ 121 as in [ 131. Partially purified (approx. 
1 pU/pg) MSA was obtained by gel chromatography 
(Sephadex G-50, 1 M acetic acid) of the conditioned 
medium from BRL3A cells. Sm activity of 1 $J is 
defined in terms of its insulin-like action as being 
equivalent to 1 #_I of porcine insulin standard in 
promoting glucose oxidation in isolated rat adipocytes. 
2.3, Chromatography 
A 1 g aliquot of the lyophilized powder (equivalent 
to approx. 80 ml) was reconstituted in 4.0 ml of 0.15 M 
ammonium acetate, pH 7.0, and centrifuged to 
remove particulate material. A 3.6 ml aliquot of the 
supernatant (approx. 8 mg protein) was subsequently 
incubated with 75 000 cpm ‘251-IFG-I (approx. 2.5 ng) 
for 18 h at 4°C. This sample was applied to a 2.5 X 
134 cm Sephacryl S-200 (Pharmacia) column equili- 
brated in and eluted with 0.15 M ammonium acetate, 
pH 7.0, at 4°C. 
2.4. Competitive protein binding assay 
Estimation of SmBP activity was determined as in 
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[13]. Briefly, the binding of ‘251-IGF-I by a sample of 
SmBP isolated from conditioned medium is quanti- 
tated by comparing it with that of known standards 
of partially purified human SmBP, 1 pg of which 
binds 30% of approx. 0.2 ng of rZSI-IGF-I. 
2.5. Analytical gel electrophoresis 
Electrophoresis was carried out for 2 h at 3 mA/ 
tube in a 10% polyacrylamide gel system, pH 8.5, as 
in [ 141. Subsequently, gels were either stained for 
protein with Coomassie blue or sliced in 1 mm sec- 
tions using an electrophoresis gel slicer (Bio-Bad, 
Richmond, CA). Individual slices were minced, trans- 
ferred to disposable glass culture tubes (12 X 75 mm) 
and suspended in 0.4 ml of 0.1 M sodium acetate buff- 
er, pH 4.0. The tubes were then capped and gently 
shaken at room temperature overnight. Binding protein 
activity of the supernatants was determined by com- 
petitive protein binding assay. 
3. Results 
The results of Sephacryl S-200 filtration at neutral 
pH of a sample of conditioned medium incubated 
with lz5 I-IGF-I are shown in fig.1 A. The elution pro- 
file of radioactivity is confined to a single peak, frac- 
tions 90-l 15, with a K, value of 0.33-0.34. In 
addition to containing approx. 95% of the radioac- 
tively labeled peptide added, this peak constituted 
about 0.04% of the total protein applied and eluted 
well before ‘free’ lz5 I-IGF-I (K,, = 0.64-0.66) as 
determined in a separate run. Binding protein activity 
of individual fractions from a similar chromatographic 
separation (but without added 12sI-IGF-I) was deter- 
mined by competitive protein binding assay (fig.1 B). 
This band of BP activity includes, but is broader than, 
the 12SI-IGF-I complexed peak seen in fig.lA. The 
specificity of the BP activity in the K,, = 0.33-0.34 
peakis demonstrated by the displacement of ‘*‘I-IGF-I 
by increasing amounts of added unlabeled MSA 
(table 1). 
An estimation of the apparent Mr of the K, = 
0.33-0.34 peak is presented in fig.2. From a plot of 
the K,, of various protein standards vs their known 
M,, we calculate that the peak of SmBP activity has 
a Mr of 45 000 + 4000 based on multiple determina- 
tions. 
Polyacrylamide gel electrophoresis was utilized in 
an attempt to further analyze the S-200 peak of SmBP 
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Fig.1. Chromatography of rat H-35 hepatoma conditioned 
medium on Sephacryl S-200 in 0.15 M ammonium acetate, 
pH 7.0. Samples were prepared and chromatographed as in 
section 2. Fraction size: 4.1 ml; flow rate: 35 ml/h. (A) 
Binding profile after prechromatography incubation with 
1251-IGF-I. Fractions were monitored individually for radio- 
activity. (B) Binding profile in the absence of added ‘251-IGF-I 
as determined by competitive protein binding assay. Column 
markers were ovalbumin (OV), a-chymotrypsinogen A (CHY 
A) and rz51-labeled IGF-I (rl’I-IGF-I). 
activity (fractions 90-l 15). A single sharp peak of 
BP activity was detected in a region corresponding to 
a discrete protein band in a parallel stained gel (fig.3). 
The band of BP activity has an RF value near to but 
slightly greater than rat serum albumin. 
Table 1 
Displacement of ‘2sI-IGF-I from H-35 hepatoma SmBP by 
added unlabeled MSA 
MSA addeda 
@g) 
0 
20 
50 
‘251-IGF-I boundb 
(70 of maximum) 
100 
40 
23 
a 1 NM 
b Determined by competitive protein binding assay 
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Fig.2. Estimation of the &$-value of rat H-35 hepatoma bind- 
ing protein by chromatography on Sephacryl S-200. Sample 
preparation and chromatography conditions are the same as 
given in fig.lA. Logarithm of the Mr-value of multiple pro- 
tein standards YS their K, (Kav = ( Ve-Vo)/( Vt-V,); 
Ve, elution volume; V,, void volume; Vt, total bed volume) 
is plotted and yielded a straight line which is used to estimate 
the k&-value of the BP. In addition to bovine thyroglobulin 
(750 000) and tyrosine to determine the V, and the Vt, 
respectively, the following peptide or protein standards from 
left to right were used: ‘zsl-IGF-I (7500),or-lactalbumin 
(14 400), cu-chymotrypsinogen A (25 000) and ovalbumin 
(45 000). Arrow, elution position of the hepatome SmBP. 
4. Discussion 
A SmBP has been partially purified and character- 
ized from SFM conditioned by cultured rat H-35 
hepatoma cells. The H-35 hepatoma cell line reported 
here resembles the BRL3A-2 subclone in that neither 
produce Sm, but both produce a SmBP eluting as a 
single peak of ‘251-Sm-complexed activity on gel 
filtration analysis [6,15]. However, these SmPBs 
appear to differ in their respective apparentMr values, 
the H-35 hepatoma SmBP complex having an apparent 
M, of approx. 45 000 on Sephacryl S-200 vs an 
apparent &fr of approx. 60 000 for both the BRG3A-2 
and BRL3A SmBP complexes. The latter, consists of 
two distinct proteins with MI values of 30 000 and 
3 1 500 in sodium dodecyl sulfate-polyacrylamide 
gels [ Ill. Under non-denaturing conditions, both the 
BRL3A-2 and BRL3A SmBPs resemble in size the 
smaller SmBP (M, x 60 000) reported in growth 
hormone-deficient serum. In vivo growth hormone 
treatment shifts the size of the SmBP present in the 
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Fig.3. Distribution of H-35 hepatoma SmBP activity in a 
polyacrylamide disc gel electrophoresed at pH 8.5. Pooled 
and lyophilized Sephacryl S-200 fractions 90-l 15 (fig.lB) 
were reconstituted in 150 ~1 of pH 8.5 running buffer. 
Aliquots of 50 ~1 (100 pg protein) were electrophoresed for 
2 h at 3 mA/tube. One of the gels was stained for protein 
(upper section); the other was sliced into 1 mm sections, 
extracted and then assayed for SmBP activity (lower section) 
as described in text. A drawing of the stained gel is at the top 
of the figure. Arrow, protein band associated with SmBP 
activity. 
latter to the larger form (M, x 150 000) found in 
normal serum [6,7]. While growth hormone stimulates 
Sm production in cultured primary hepatocytes [9], 
we have not yet tested its influence on either Sm or 
SmBP production by H-35 hepatoma cells. 
Treatment of human and rat serum with acid shifts 
the SmBP from the larger to smaller Mr species, sug- 
gesting the larger form is acid labile [5-71. Prechro- 
matographic incubation of H-35 conditioned SFM 
with ‘251-IGF-I followed by Sephacryl S-200 chro- 
matography under acid conditions @H 4.0) similarly 
shifts the radioactive complex seen under pH 7 .O con- 
ditions to a smaller size (M, x 19 000) (data not 
shown). This suggests the Mr x 45 000 species both 
is acid labile and therefore distinct from the low Mr 
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SmBP in serum, and subdividable into smaller com- 
ponents which retain binding activity. 
Data from this and previous studies provide evi- 
dence that SmPBs, like the Sms themselves, constitute 
a family of forms which at this time are not fully 
understood with respect to their structure and func- 
tion. We believe that the H-35 hepatoma cell line 
offers a unique model for the study of a previously 
undescribed, acid-labile, low M, SmBP. The synthesis 
of this protein in the absence of Sm provides a signifi- 
cant advantage for its isolation without prior cleavage 
of its l&and. 
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